Caris FOLFIRSTai
Use
Caris FOLFIRSTai is developed as an AI-based molecular predictor aimed at identifying the likely efficacy of chemotherapy in patients with metastatic colorectal cancer (mCRC). It offers oncologists guidance on choosing between two common chemotherapy regimens, FOLFOX+BV followed by FOLFIRI+BV or the reverse, based on the molecular profile of the patient's tumor. This test is targeted towards enhancing overall survival by aligning treatment with the regimen predicted to offer the best benefit.
Special Instructions
Caris FOLFIRSTai is included at no additional cost, increased turnaround time, or additional specimen requirements for Caris molecular profiling mCRC cases. It is an integral part of the molecular profiling order for mCRC patients.
Limitations
The test results should not be the sole basis for treatment decisions; they need to be interpreted in conjunction with clinical context. The efficacy of chemotherapy predicted by FOLFIRSTai may vary between patients due to numerous factors involving individual patient conditions and other variables not accounted for by the test.
Methodology
Other
Biomarkers
Result Turnaround Time
Not provided.
Related Documents
For more information, please review the documents below
Specimen
Tissue (FFPE)
Volume
Not provided
Minimum Volume
Not provided
Collection Instructions
Molecular testing is performed after microdissection of targeted tissues from paraffin blocks.
Other tests from different labs that may be relevant